---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-009085"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2025-07-03T23:59:59+00:00"
generated_at: "2026-05-18T09:27:00.893333+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coherus Oncology receives Nasdaq bid price deficiency notice; 180 days to regain compliance

## Summary
- On June 30, 2025, Nasdaq notified Coherus that its common stock closed below $1.00 for 30 consecutive business days.
- Company has until December 29, 2025 to regain compliance by closing at $1.00+ for 10 consecutive days.
- If not compliant by deadline, Coherus may qualify for an additional 180-day period by transferring to Nasdaq Capital Market.
- Failure to cure could lead to delisting; company intends to monitor bid price and evaluate options.

## SEC filing metadata
- accession: 0001558370-25-009085
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2025-07-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837025009085/0001558370-25-009085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837025009085/chrs-20250630x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-009085
- JSON: https://secwatch.observer/filing/0001558370-25-009085.json
- Plain text: https://secwatch.observer/filing/0001558370-25-009085.txt

## Key facts
- Listing & Compliance Notices
  Coherus Oncology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: June 30, 2025, Coherus Oncology, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1).The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Market. ​ In accordance with Nasdaq Listi
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837025009085/0001558370-25-009085-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.